Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Ultragenyx Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters’ Option To Purchase Additional Shares
Article By:
NASDAQ GlobeNewswire
Monday, November 2, 2020 2:22 PM EDT
Ultragenyx Pharmaceutical Inc., today announced the closing of its previously announced underwritten public offering of 5,111,110 shares of its common stock, including the exercise in full by the underwriters of their option.
In this article: RARE
The Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke, And Ultragenyx
Article By:
Benzinga
Sunday, June 14, 2020 3:13 PM EDT
Biotech stocks came under pressure along with the broader market in the week that ended June 12, as a worsening pandemic situation and its impact on the economy led to an across-the-board sell-off in the global markets.
In this article: MRK, EVOK, RARE, EPZM Also: AZN, GILD, BMY, SNY, RPRX, CELG, PRQR, NBRV, CBIO, UROV, CNTG
Ultragenyx Pharmaceutical Reports Positive Phase III Data For Their Kyowa Hakko Kirin-Partnered Drug
Article By:
Lorimer Wilson
Thursday, April 20, 2017 2:54 AM EDT
Ultragenyx Pharmaceutical Inc. has reported clearly positive Phase III data for their Kyowa Hakko Kirin-partnered drug for X-linked hypophosphatemia, and now they plan to hustle that data package to regulators at the FDA and EMA.
In this article: RARE